- Poster presentation
- Open Access
Monomyeloid precursors in drug-induced hypersensitivity syndrome
- Hideo Hashizume1
© Hashizume; licensee BioMed Central Ltd. 2014
Published: 18 July 2014
Drug-induced hypersensitivity syndrome (DIHS), also known as drug reactions with eosinophila and systemic symptoms, has unique clinical features including fever, generalized rash, lymphadenopathy and extracutaneous organ involvements. During the disease course, human herpesvirus (HHV)-6 reactivation is frequently (60%<) observed in association with unfavorable outcomes. We recently noticed a transient increase of circulating monocyte-sized cells that showed higher side scatter counts in flowcytometer analysis before HHV-6 reactivations. These cells were CD14lowCD16+, like a minor (<10%) monocyte subset that differentiates into 'resident' dendritic cells/macrophages, but were CD4- CD11a- CD11b+ CD13int CD34- CD41ab- CD66b- CD117- CD163- and contained rich organelles histologically, suggesting mono-myeloid precursors, not bona fide monocytes. We also found HHV-6 genome and antigens in them. Since mono-myeloid cells in the bone marrow are reportedly reservoirs of HHV-6, the mono-myeloid precursors that emerged transiently in circulation in DIHS patients might emigrate from the bone marrow, and are suggested to play a special role of the virus reactivation. Our observations will provide a scenario that circulating mono-myeloid precursors bridge between drug allergy and viral infection, which remains poorly understood, in DIHS.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.